Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes
Authors' conclusion
We conclude that use of semaglutide in patients who are OW and/or OB with T1D was effective in lowering body weight and BMI, and improving glycemic metrics in this pilot real-world study.
Study context
- Population
- Overweight or obese patients with T1D; 92% non-Hispanic white; mean age 42 ± 11 years, diabetes duration 27 ± 12 yearsmatched controls
- Participants
- 50 vs 50
- Exposure
- Semaglutide vs no weight loss medication
- Semaglutiden = 50
- Controln = 50reference
- Outcome
- Change in BMI, body weight and glycaemic metrics
- Follow-up
- 1 year
Methodological detailsmatched controls (sex, race, weight, body mass index (BMI), diabetes duration), real-world, pilot
- Matched controls (sex, race, weight, BMI, diabetes duration)
- Real-world
- Pilot
Main finding
As reported in the abstract
Significantly greater decline in BMI with semaglutide vs control (mean ± SD)
7.9% ± 2.6%
Significantly greater decline in body weight with semaglutide vs control (mean ± SD)
15.9 lbs ± 5.4 lbs
Observational data: associations, not effects.
Further findings
Baseline HbA1c · insignificantly lower with semaglutide
P = non-significant [NS]
Baseline insulin dose
- TDD and insulin dose per kg higher with semaglutide at baseline; no difference in basal or prandial dose
Original publication
Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →